A detailed history of China Universal Asset Management Co., Ltd. transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 17,505 shares of RCKT stock, worth $205,858. This represents 0.04% of its overall portfolio holdings.

Number of Shares
17,505
Previous 10,666 64.12%
Holding current value
$205,858
Previous $229,000 41.05%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$17.6 - $25.88 $120,366 - $176,993
6,839 Added 64.12%
17,505 $323,000
Q2 2024

Jul 19, 2024

SELL
$20.66 - $26.72 $138,401 - $178,997
-6,699 Reduced 38.58%
10,666 $229,000
Q1 2024

Apr 29, 2024

BUY
$26.16 - $30.74 $181,576 - $213,366
6,941 Added 66.59%
17,365 $468,000
Q4 2023

May 21, 2024

SELL
$16.78 - $31.94 $116,469 - $221,695
-6,941 Reduced 39.97%
10,424 $312,000
Q4 2023

Jan 23, 2024

BUY
$16.78 - $31.94 $140,213 - $266,890
8,356 Added 404.06%
10,424 $312,000
Q3 2023

May 21, 2024

BUY
$15.07 - $24.05 $15,280 - $24,386
1,014 Added 96.2%
2,068 $42,000
Q3 2023

Oct 30, 2023

BUY
$15.07 - $24.05 $15,280 - $24,386
1,014 Added 96.2%
2,068 $42,000
Q2 2023

May 21, 2024

SELL
$16.59 - $23.6 $348 - $495
-21 Reduced 1.95%
1,054 $20,000
Q2 2023

Jul 27, 2023

SELL
$16.59 - $23.6 $348 - $495
-21 Reduced 1.95%
1,054 $21,000
Q1 2023

May 21, 2024

BUY
$15.79 - $22.6 $4,831 - $6,915
306 Added 39.79%
1,075 $18,000
Q1 2023

Apr 27, 2023

BUY
$15.79 - $22.6 $4,831 - $6,915
306 Added 39.79%
1,075 $18,000
Q4 2022

May 21, 2024

SELL
$15.5 - $22.76 $257,238 - $377,724
-16,596 Reduced 95.57%
769 $15,000
Q4 2022

Jan 31, 2023

BUY
$15.5 - $22.76 $2,340 - $3,436
151 Added 24.43%
769 $15,000
Q3 2022

Oct 21, 2022

BUY
$12.37 - $18.41 $7,644 - $11,377
618 New
618 $10,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $890M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.